All In Biotech

NDA 021385 · Lacer Pharma

Ertaczo

Sertaconazole Nitrate · Topical

Novel

Last checked: Nov 19, 2026Latest source record: Dec 17, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Dec 10, 2003

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3

1 Phase 3, 0 recruiting

FAERS reports

162

124 serious, 21 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 7, 2026.

ERTACZO ® cream, 2%, is indicated for the topical treatment of interdigital tinea pedis in immunocompetent adult and pediatric patients 12 years of age and older caused by Trichophyton rubrum , Trichophyton mentagrophytes, and Epidermophyton floccosum . ERTACZO cream, 2% is an azole antifungal indicated for the topical treatment of interdigital tinea pedis in immunocompetent adult and pediatric patients 12 years of age and older caused by Trichophyton rubrum, Trichophyton mentagrophytes , and Epidermophyton floccosum . ( 1 )

Mechanism: Sertaconazole nitrate is an azole antifungal [see Clinical Pharmacology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 10, 2003 Original approval · Type 1 - New Molecular Entity NovelReviewLetterLabel
1 products under this application
  • ERTACZO · SERTACONAZOLE NITRATE 2% · CREAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sertaconazole Nitrate" as an intervention, any sponsor and status, largest first.

All 3 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue15
  • off label use15
  • urethral valves14
  • fall13
  • rash12
  • weight decreased11
  • asthenia10
  • gait disturbance10
  • nausea10
  • dizziness9
  • erythema9
  • pruritus9

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20052
20061
20082
20093
20103
20112
20122
201310
20141
20166
20174
20183
20196
20202
20218
202227
202326
202425
202516
202613

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ertaczo (Sertaconazole Nitrate)

2024 spending

$4.9M

Beneficiaries

1,663

4,137 claims

Per beneficiary

$2,957

$14.06 per unit

View as table
YearSpending
2020$429,250
2021$296,437
2022$301,496
2023$941,806
2024$4,917,777

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8 on PubMed

Sponsor: Lacer Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.